This invention introduces chemically modified polymeric nanoparticles loaded with siRNA and chemotherapy drugs for aggressive cancer treatment. The modification enhances siRNA stability, while POL2RA silencing downregulates CDK, triggering cancer cell death. These multi-targeted nanoparticles show strong potential for advanced cancer therapy, warranting further clinical studies.
TRL
Number of units currently deployed
No. of days or hours of training required
For any queries or concerns, please submit your message using the form below. Our team will review your submission and respond at the earliest.
Contact DeveloperProf. Pradip Paik School of Biomedical Engineering, Indian Institute of Technology (BHU), Varanasi Email: paik[dot]bme[at]iitbhu[dot]ac[dot]in |